LL schreef op 10 augustus 2021 20:15:
[...]
achtergrond info:
Huidige markt US is ongeveer 60% Profylaxe.
Operator
Next question is from the line of Brian Cheng of Cantor Fitizgerald. Your line is now open.
Brian Cheng
Good morning, team. Congrats on another quick quarter. And thanks for taking my question. So you're seeing patients adopting and switching from both prophy and on-demand options trial ORLADEYO.
We're just curious, how you're thinking about the on-demand versus prophy you're going to shakeout in the next few years? And can you comment on how the patient access through medical exception versus formula reach has changed this quarter versus last quarter? And I have a quick follow-up. Thanks.
Jon Stonehouse
Charlie, I'll take the first one you take the second. So, Brian with regard to prophy and on-demand market, it's shrinking every day. And it's not just us that are shrinking, it Takeda, CSL with their prophylactic therapy.
So, honestly, we said 80/20 ultimately when it settles out it. Could it could be 90/10 just given how patients really -- I think they always wanted prophylactic therapy. They want to prevent attacks. And now that there's an oral option, we're just seeing a lot of enthusiasm.